Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center. The candidate should have a doctoral degree such as MD or PhD or equivalent degree and has interests in cancer biology. The research involves understanding the role of mitochondria in multiple myeloma pathogenesis and developing immunotherapy (checkpoint inhibitors and CAR T) and novel agents for the treatment of multiple myeloma. The overall duties and responsibilities are: 1) to develop novel approaches for treating multiple myeloma; 2) to perform experiments and collect data, and to evaluate experimental data and establish the relevance to experimental problems under investigation; 3) to prepare research results for publication in reports, papers, journals, books, and other media; and 4) to train and direct support personnel. The candidates are expected to have training or experience in genetically modified mouse models, animal bone marrow transplant models, flow cytometry, immunohistochemical staining, and lentiviral-based gene transfer. Prior experiences in confocal microscope and electronic microscope techniques are a plus.
Duke University is an Affirmative Action/Equal Opportunity Employer committed to providing employment opportunity without regard to an individual's age, color, disability, gender, gender expression, gender identity, genetic information, national origin, race, religion, sex, sexual orientation, or veteran status.
Duke aspires to create a community built on collaboration, innovation, creativity, and belonging. Our collective success depends on the robust exchange of ideas-an exchange that is best when the rich diversity of our perspectives, backgrounds, and experiences flourishes. To achieve this exchange, it is essential that all members of the community feel secure and welcome, that the contributions of all individuals are respected, and that all voices are heard. All members of our community have a responsibility to uphold these values. |
finished (2019/01/31, finished 2019/11/03, listed until 2019/07/31)